March 04, 2015
On March 2, 2015, Johnson & Johnson announced a binding offer from Cardinal Health to acquire its Cordis business for an aggregate value of $1.99 billion, consisting of $1.944 billion of cash proceeds from Cardinal Health plus approximately $46 million of retained net receivables. Cravath is representing Johnson & Johnson in connection with this transaction. The acceptance period for the offer will end on May 30, 2015, unless extended. If the offer is accepted, the proposed transaction would be expected to close towards the end of 2015, subject to customary closing conditions and regulatory approvals.
The Cravath team was led by partner Robert I. Townsend III and included associate Nicholas A. Dorsey on M&A matters; partner Eric W. Hilfers, senior attorney Jarrett R. Hoffman and associate Matthew J. Bobby on executive compensation and benefits matters; partner David J. Kappos and associate Nicholas A. Jackson on intellectual property matters; and partner Matthew Morreale on environmental matters. Adam J. Gross also worked on M&A matters.
Deals & Cases
March 12, 2025
Cravath represented the underwriters in connection with the $5 billion registered notes offering of Johnson & Johnson, the world’s largest, most diversified healthcare products company. Cravath also represented the underwriters in connection with Johnson & Johnson’s concurrent €4 billion notes offering. Proceeds of both offerings will be used to finance the acquisition of Intra‑Cellular Therapies, Inc. by Johnson & Johnson. The transactions closed on February 20, 2025, and February 26, 2025, respectively.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.